MedTrace Logo

Evaluation of Woulgan in Diabetic Foot Ulcer

NCT02631512 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-05-30

No results posted yet for this study

Summary

The aim of the current study is to support the performance and safety of Woulgan® in the treatment of diabetic foot ulcer in comparison with the commercially available hydrogel Intrasite. Healing and untoward medical events to be evaluated.

Conditions

  • Diabetic Foot Ulcers

Interventions

DEVICE

Woulgan Gel

Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.

DEVICE

Intrasite Hydrogel

Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage

Sponsors & Collaborators

  • Biotec Pharmacon ASA

    lead INDUSTRY

Principal Investigators

  • Magnus Londahl, MD, PhD · Skane University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-12-31
Completion
2019-04-30

Countries

  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631512 on ClinicalTrials.gov